Financial Implications of COVID-19 Polymerase Chain Reaction Tests on Independent Laboratories

During the COVID-19 pandemic, independent laboratories provided critically needed polymerase chain reaction (PCR) tests (Current Procedure Terminology Code: 87635) to identify positive COVID-19 patients. The Families First and Coronavirus Relief Act and CARES Act require commercial insurance plans to cover COVID-19 testing costs without any cost-sharing for patients, but do not set the price.1,2 Prior research has examined the variation in charges for PCR tests in laboratories.3 However, their financial return from COVID-19 testing remains unexplored. Using the unique taxation data from Hawaii, we analyzed how the COVID-19 pandemic affected the revenue and profitability of independent laboratories.

Halliday, T., Tan, C., Juarez, R. et al. Financial Implications of COVID-19 Polymerase Chain Reaction Tests on Independent Laboratories. Journal of General Internal Medicine (2022).


Leave a Comment

Your email address will not be published.

The University of Hawaii Economic Research Organization (UHERO) welcomes online comments to stories that are posted on our website or social media pages. Comments are intended to be a forum for open, respectful, and family-friendly discussion. UHERO reserves the right to remove anything posted on our website or social media pages that is deemed inappropriate. All comments are moderated and will therefore have a delayed post time.
Some guidelines (not an exhaustive list) we use when moderating/approving comments include:

  • Do not bully, intimidate, or harass any user.
  • Do not post content that is hateful, threatening or wildly off-topic; or do anything unlawful, malicious, discriminatory or defamatory.
  • Observe confidentiality laws at all times.
  • Do not post spam or advertisements.
  • Observe fair use, copyright and disclosure laws.
  • Do not use vulgar language or profanity.

UHERO may amend this policy from time to time.